Thailand’s Compulsory Licensing Controversy

Between November 2006 and January 2007, Thailand issued compulsory licenses for two AIDS drugs (efavirnz and the combination of lopinavir+ritonavir) and one antihypertension drug (clopidegrel).  The pharmaceutical industry has vehemently objected to these compulsory licenses, and has sought the US… Continue Reading

Notes from March 16th 2007 U.S. Capitol Briefing on Thailand’s Compulsory Licenses

On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). … Continue Reading

European Commission Response to CPTech Letter Regarding EU Opt-out of WTO Compulsory Licensing Mechanism

Original page: http://www.cptech.org/ip/wto/p6/eu12052005.pdf Letter from CPTech referenced available here: https://www.keionline.org/32641 MARKOS KYPRIANOU                                            PETER MANDELSON Member of the European Commission … Continue Reading